- 专利标题： Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
-
申请号： US16322712申请日： 2017-07-20
-
公开(公告)号： US11066479B2公开(公告)日： 2021-07-20
- 发明人: Mitchell Ho , Nan Li , Dimiter S. Dimitrov
- 申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 申请人地址： US MD Bethesda
- 专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 代理机构： Klarquist Sparkman, LLP
- 国际申请： PCT/US2017/043112 WO 20170720
- 国际公布： WO2018/026533 WO 20180208
- 主分类号： C07K16/30
- IPC分类号： C07K16/30 ; A61K47/69 ; A61K47/64 ; A61P35/00 ; C07K7/08 ; C07K16/28
摘要：
A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of Pseudomonas exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.
公开/授权文献
信息查询
